quote:

+ schreef op 4 februari 2012 20:25:

Las laatst een keer(kan het niet vinden ) dat Biolex krap bij kas zat.
Nu hebben ze een paar weken terug geld opgehaald t.b.v. SEC-Filling.
Investeerders geven/gaven 10milj. Doe er wat mee dan!!! www.biolex.com/products-.htm

apps.firstrain.com/SeekingAlpha/001/d...
Krap bij kas zit Biolex imho nog steeds.
10 mil. tbv de toezichthouder, amai…..
5.9 van een paar weken terug is iets langer geleden(06-2011) en van de aangeboden 3.2 is 2.4 "verpatst".

www.sec.gov/cgi-bin/browse-edgar?acti...
www.sec.gov/answers/rule506.htm
Clarus Ventures-backed Biolex Therapeutics Raises 75% of $3.2M Offering
Biolex Therapeutics Inc. has raised $2.4 million, or 75 percent of a $3.2 million debt offering, from 10 investors, according to an SEC filing.

Principals named in the filing by the Pittsboro, N.C.-based drug developer are:

• Chairman P. Sheriff Neff;
• Executive Chairman Kurt Graves;
• President and CEO Jan Turek;
• COO David Spencer;
• CFO Dale Sander;
• Director Dennis Dougherty of Durham, N.C.-based Intersouth Partners;
• Director W. Amick, an advisor to Intersouth Partners and Philadelphia-based Quaker BioVentures;
• Jeffrey Leiden of Cambridge, Mass.-based Clarus Ventures;
• Director David Castaldi, an entrepreneur and former president of Baxter International; and
• Liza Nelson of Sweden's Investor Growth Capital with offices in New York.
In June, the company raised $5.9 million through a sale of debt and convertible securities.

Biolex Therapeutics is a clinical-stage biopharmaceutical company that uses its patented LEX System to develop follow-on biologics, hard-to-make therapeutic proteins and monoclonal antibodies that have been optimized to enhance their efficacy and potency. The LEX System is a novel technology that genetically transforms the aquatic plant Lemna to enable the production of biologic product candidates.